People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. | — | Pharmaceuticals | Series C | $91.3M | $2.8B | 2011 |
| Barosense Inc | — | Biotechnology | Series B | $56.9M | $1.2B | 2009 |
| Envisia Therapeutics, Inc. | — | Biotechnology | Series A | $14.7M | $365.8M | 2015 |
| Cereius, Inc. | — | Biotechnology | Seed | $1.0M | $44.4M | 2018 |
Eric Linsley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric Linsley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Bloch | 1 | 15 |
| Ed Mathers | 1 | 11 |
| Alan Levy | 1 | 7 |
| Adrienne Graves | 1 | 6 |
| Seth Rudnick | 1 | 5 |
| Scott Weiner | 1 | 4 |
| John Onopchenko | 1 | 4 |
| Gary Phillips | 1 | 4 |
| Neal Fowler | 1 | 4 |
| Paul Truex | 1 | 3 |
| William Yelle | 1 | 2 |
| Kimberly Blackwell | 1 | 2 |
| Edward Field | 1 | 2 |
| Martin Maguire | 1 | 1 |
| Yves Rosconi | 1 | 1 |
| Francis Plat | 1 | 1 |
| Dominic Jaikaran | 1 | 1 |
| Douglas Wight | 1 | 1 |
| Benjamin Cowen | 1 | 1 |
| Nathalie Beauregard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.